Beijing, China, June 17, 2026 — Jacobio Pharma (1167.HK) today announced that its CMC team recently visited Pharmaron’s Shaoxing manufacturing facility for business discussions with the Pharmaron team. Previously, the two parties had entered into a collaboration agreement, under which Pharmaron will initiate the manufacturing of clinical trial materials for JAB-23E73, Jacobio’s Pan-KRAS inhibitor, for registrational clinical trials. Pharmaron will also support CMC process development and validation work related to new drug applications for Jacobio’s potential commercial-stage products.

Jacobio Pharma commented, “This strategic collaboration will further strengthen our capabilities in drug process development and clinical supply chain management, laying a solid foundation for the advancement of future pivotal clinical trials and commercialization. Going forward, Jacobio will continue to advance the development of its core pipeline and remains committed to providing innovative treatment options for patients.”
Pharmaron commented, “Pharmaron has accumulated extensive experience in process development and clinical supply, while continuing to strengthen its commercial-scale manufacturing capabilities. Pan-KRAS is an important target in oncology with significant clinical demand and market potential. Pharmaron will assign a first-class team to fully support the project and ensure its successful execution.”

About Jacobio

Jacobio Pharmaceuticals Co., Ltd., headquartered in Beijing, focuses on the R & D of innovative medicines, It dedicates to provide breakthrough innovations to treat major diseases and bring more solutions to promote human health. The vision of Jacobio is to become a global leader in pharmaceutical industry. Jacobio has established an R & D center in Boston, USA, to strengthen and coordinate the global development of new drugs.